SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-072188
Filing Date
2022-11-14
Accepted
2022-11-14 16:08:35
Documents
51
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0922_tffpharma.htm   iXBRL 10-Q 730461
2 CERTIFICATION f10q0922ex31-1_tffpharma.htm EX-31.1 11718
3 CERTIFICATION f10q0922ex31-2_tffpharma.htm EX-31.2 11836
4 CERTIFICATION f10q0922ex32-1_tffpharma.htm EX-32.1 5629
5 GRAPHIC image_001.jpg GRAPHIC 2359
  Complete submission text file 0001213900-22-072188.txt   3408970

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20220930.xsd EX-101.SCH 45099
7 XBRL CALCULATION FILE tffp-20220930_cal.xml EX-101.CAL 23072
8 XBRL DEFINITION FILE tffp-20220930_def.xml EX-101.DEF 156134
9 XBRL LABEL FILE tffp-20220930_lab.xml EX-101.LAB 363557
10 XBRL PRESENTATION FILE tffp-20220930_pre.xml EX-101.PRE 168298
45 EXTRACTED XBRL INSTANCE DOCUMENT f10q0922_tffpharma_htm.xml XML 307192
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 221385208
SIC: 2834 Pharmaceutical Preparations